Bloomberg Law speaks with prominent attorneys and legal scholars, analyzing major legal issues and cases in the news. The show examines all aspects of the legal profession, from intellectual property to criminal law, from bankruptcy to securities law, drawing on the deep research tools of BloombergLaw.com and BloombergBNA.com. Reporters from Bloomberg's Washington, D.C. bureau are prominently featured as they offer analysis of policy and legal issues.
Renowned financier, Co-Founder of The Carlyle Group, and philanthropist David Rubenstein provides unparalleled access to the world's most successful investors. In one-on-one interviews, Rubenstein will learn investing strategies and tactics from some of the world's top wealth creators.
Australia’s Recession Risk Spikes as RBA Peak Rate Seen at 4.35%
Pakistan to Push Growth to 3.5% Amid IMF Austerity Measures
Bank of Canada Suggests Higher Rates May Not Have as Much Bite
Manulife’s Donald Rues Bank of Canada Hike, Sees Recession Soon
Central Banks Across Latin America Get Welcome Inflation News
Visa Nearing Deal for Brazil Payments Provider Pismo, Sources Say
China’s BYD Launches Fang Cheng Bao ‘Formula Leopard’ Range
Chip Titan TSMC's First Factory in Japan Has to Contend With Horrible Traffic
What Trump’s Indictment Means for His 2024 Presidential Run
Donald Trump Charged in Florida Over Secret Documents Case
Tiger Global Among Hedge Funds Riding AI Mania to May Gains
Bank of America Reworks Leadership in Investment Bank Unit
Taylor Swift, Drake May See Streaming Pay Rise Under New Plan
At PGA Tournament, All Anyone Wants to Talk About Is LIV Golf
How Do You End Sri Lanka’s Crisis? Ask the Bond Market
Forget Bears and Bulls, We’re in a Shrimp Market
What Australia’s Wildfires Can — and Can’t — Teach a Smoky US
The Netflix Effect Chills Foreign Content Creators
Payrolls, Prices, Productivity and Profits Hold the Answer to the Puzzling US Economy
Will Argentina Ditch the Peso for the Dollar?
How Aid for Poor Nations With Big Debts Got Stuck
Bali Seeks a New Kind of Tourist After Kicking Out 136 Unruly Visitors This Year
Plan for One of World’s Biggest Coal Mines Challenged in India
Climate Talks Chief Al Jaber Says Fossil Fuel Decline Inevitable
Connecticut May Ban Collection Tactic Used in Cash-Advance Loans
Deep Drought Punishes Latin American Clean Water Pioneer
A Forgotten Monument to Times Square Flickers Back to Life
FTX’s US Judge Vows to Keep Control of Crypto in Blow to Bahamas
SEC Seeks ‘Alternative Means’ to Serve Papers to Binance’s Zhao
Bitcoin Liquidity Worsens on Crypto Exchange Binance.US After SEC Suit
Clinuvel Pharmaceuticals Ltd. surged the most in five years after the U.S. Food and Drug Administration approved its treatment for a rare skin disorder that causes sensitivity to light.
Shares of the Melbourne-based bio-pharmaceutical firm jumped as much as 57% in Sydney, the most since October 2014, after the U.S. allowed the use of the drug Scenesse to treat erythropoietic protoporphyria. Clinuvel rose to a record high of A$44.39, valuing the company at A$2.2 billion ($1.5 billion).